Hec585 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04512170 (ClinicalTrials.gov) | July 13, 2020 | 7/8/2020 | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects | A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Randomized, Open-label,Crossover, Food Effect Study of HEC585 in Healthy Chinese Subjects | Idiopathic Pulmonary Fibrosis | Drug: HEC585 | Sunshine Lake Pharma Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 58 | Phase 1 | China |
| 2 | NCT03092102 (ClinicalTrials.gov) | May 20, 2017 | 21/3/2017 | The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | Idiopathic Pulmonary Fibrosis | Drug: HEC585 | Sunshine Lake Pharma Co., Ltd. | NULL | Completed | 18 Years | 60 Years | All | 136 | Phase 1 | United States |